PHA Welcomes Scholarship Applicants for Its 2016 Conference

The Pulmonary Hypertension Association’s International PH Conference and Scientific Sessions is one of the largest gatherings on pulmonary hypertension (PH) worldwide, bringing patients, caregivers and top healthcare professionals together to share stories, exchange information, and network. Planning for the 2016 conference, to take place in Dallas, Texas, from June 17-19, is getting underway, and PAH is again helping PH patients attend through its Conference Scholarship Fund.

In 2014, the scholarship program assisted 350 patients and caregivers who otherwise wouldn’t have been able to attend that year’s event. Scholarship applications for next year’s conference are now being accepted, and the PHA wants to get the word out to as many potential attendees as possible.

“Thank you so much for providing me the opportunity to attend my first PH conference. It was a fantastic experience and I learned so much. I am looking forward to the next conference in Dallas. Thank you again for blessing me in so many ways!” said a 2014 attendee through the Conference Scholarship Program.

Eligible scholarship applicants are PH patients or a caregiver to a child with PH, or PHA members. People who attended the   2014 Conference on a full scholarship are not eligible to reapply for 2016, although a current Support Group Leader can apply for registration assistance. People who received scholarships in years other than 2014 are eligible to apply beginning March 1, 2016.  Conference Scholarship Fund applications can be found here.

Those unsure about their eligibility are asked to contact the PHA’s office by calling 301-565-3004 ext. 763 or by using e-mail.

Para completar la aplicación en español, use este formulario.

The Pulmonary Hypertension Association is the first and leading PH association in the world, and will celebrate its 25th anniversary in 2016. The PHA’s mission is to support patients and caregivers, to further advocacy and awareness, to advance medical education and to fund research into new ways to prevent, treat and cure pulmonary hypertension.